Labiotech.eu

News and Trends 28 Jan 2016

Viral Immunotherapy Trial Failure Causes French Biotech Stocks to Drop 43%

Genticel (France) is a clinical biotech developing a cervical cancer immunotherapy against the Human papillomavirus. However, their 24-month phase II trial has failed to meet primary endpoint at its halfway point, and their stocks dropped 43% overnight. Around 70% of cervical cancer cases are caused by 2 types of Human papillomavirus (HPV): 16 and 18. And among the 300 million women around the […]

January 28, 2016 - 3 minutesmins - By Dani Bancroft

News and Trends 27 Jan 2016

French Investor Leads €60M Financial Round for the Future of DNA Synthesis

Twist Bioscience is a San Francisco Biotech accelerating science and innovation through rapid, high-quality DNA synthesis piece of tech. And now, Twist has completed a $61 million Series D round. An improved silicon-based design compared to the traditional 96-well plates could do wonders for DNA synthesis, including major improvements in cost and time of the process. And the […]

January 27, 2016 - 3 minutesmins - By Dani Bancroft

News and Trends 27 Jan 2016

New UK Joint Venture Bridges Gap between Top Universities and Big Pharmas

AstraZeneca, GlaxoSmithKline, Johnson & Johnson and the 3 world-leading universities (Imperial College London, University College London and the University of Cambridge) have joined forces to found the ‘Apollo’ Bridge. This pioneering new joint venture, the Apollo Therapeutics Fund, will support the translation of ground-breaking academic science from within these universities into innovative new medicines for […]

January 27, 2016 - 3 minutesmins - By Dani Bancroft

News and Trends 27 Jan 2016

3 Facts Showing that the Future of Biotech Media is Online

Print Media are having a hard time since the explosion of digital content. In Biotech, publishers are facing the same challenge. As a leading Biotech publication, we believe that the future of our field is online. Here are some explanations on why we think so! The first thing to look at is how the content consumption has […]

January 27, 2016 - 2 minutesmins - By Joachim Eeckhout

News and Trends 26 Jan 2016

Keytruda Combo! MSD Recruits German Biotech on Lymphoma PD-1 Trial

Affimed in Heidelberg (Germany) will fund and conduct a clinical trial to investigate the combination of Merck’s (MSD) anti-PD-1 therapy (Keytruda), with Affimed’s proprietary drug for the treatment of patients with Hodgkin lymphoma. The phase Ib trial will focus on patients whose disease has relapsed or is refractory to chemotherapy, including treatment with the marketed antibody-drug-conjugate […]

January 26, 2016 - 2 minutesmins - By Dani Bancroft

News and Trends 26 Jan 2016

Gilead On Board, But Still No Easy Sailing for Galapagos with Phase IIa Failure

Galapagos (Belgium) and Gilead (US) announced today the closing and entry into force of their global license and collaboration agreement on filgotinib, just as results are released for a phase II trial against Ulcerative colitis. Under the terms of the agreement, the closing of this transaction triggers an upfront license fee payment of $300M by Gilead […]

January 26, 2016 - 2 minutesmins - By Dani Bancroft

News and Trends 26 Jan 2016

Virtual Reality: What is the future of Biotechnology Teaching and Training?

We often cover cutting-edge advances in biotechnology, but less frequently see significant development in biotechnology education…so how about these Virtual Reality Labs in Denmark? A Danish start-up called Labster aims to disrupt the way we teach students about lab work in the hope of ‘empowering the next generation of scientists to save the world’. We caught up […]

January 26, 2016 - 4 minutesmins - By Marie Godar

News and Trends 26 Jan 2016

2011-2015: What a Fantastic 5 Years for European Biotech

The crisis of 2008 hit the Biotech sector hard, and it wasn’t clear how the Biotech industry would get back on track. But now, end of 2015, we can definitely say the Biotech industry did extremely well and probably better than most of the analysts would have predicted… So what were the major news stories […]

January 26, 2016 - 5 minutesmins - By Philip Hemme

News and Trends 25 Jan 2016

This Potential First in Class Cancer Therapy Could Help Patients Avoid Eye Surgery

Immunocore in Oxford (UK) has been Granted Orphan Drug Designation for a Phase I Super rare Eye cancer drug by the FDA. Uveal melanoma is a rare disease in which cancer cells form in the tissues of the eye, and comprises approximately 3% of all melanomas. It is actually the primary intraocular malignancy of the adult eye and currently, […]

January 25, 2016 - 2 minutesmins - By Dani Bancroft

News and Trends 25 Jan 2016

Also Using PD-L1 Cancer Treatments to Attack Alzheimer’s Disease

What updates have occurred in the Neurodegenerative disease field as of late? New appointments by the Dementia Discovery Fund, which widens its international reach – and new ‘out of the box’ ideas from Israel and South Korea. The Dementia Discovery Fund (DDF), an innovative global investment fund managed by SV Life Sciences and launched in October […]

January 25, 2016 - 3 minutesmins - By Dani Bancroft

News and Trends 25 Jan 2016

Nature’s Machines: Biohacking Evolution to Destroy Pollutants

The Concept of artificially ‘Driving Evolution’ is as contagiously controversial as it is captivating for Biotechs, DIY Biologists and iGEM teams alike. How can we harness an ‘Evolution Machine’ for the Greener Good and ‘create’ microbes to break down pollutants? At the Digital Biology (“Do it Together”) Conference last week (a European consortium for DIY Biologists and […]

January 25, 2016 - 5 minutesmins - By Dani Bancroft

News and Trends 23 Jan 2016

What happened this week? Top 8 on Cancer, Inside J.P. Morgan and our new Event

Monday: Inside Biotech’s Most Secretive Elite Conference: MorphoSys Talks on Investor Speed Dating in California Tuesday: Top 8 Deadliest Cancers and their Potential Cures Wednesday: How is Using Amoeba to Fight off Legionella in Water Tanks a White Biotech Solution? Thursday: Mologen Joins the Rapidly Growing List of EU Partners with the No#1 US Cancer Hospital Friday: […]

January 23, 2016 - 1 minutemin - By Philip Hemme

Knowledge hub

Categories

The top biotech deals of March 2025

The biggest biotech funding rounds in March 2025

Approaches

Therapeutic areas

Join the webinar: AI in antibody discovery - from in silico analysis to AI-enabled data management

Beyond amyloid: The search for the next big thing in Alzheimer’s treatment

R&D

BD

World biotech leaders

Connect with decision-makers and researchers worldwide for collaborative opportunities

Company

Join Us

Subscribe to our newsletter

Advertise with us

The top biotech deals of March 2025

The biggest biotech funding rounds in March 2025

Join the webinar: AI in antibody discovery - from in silico analysis to AI-enabled data management

Beyond amyloid: The search for the next big thing in Alzheimer’s treatment

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Viral Immunotherapy Trial Failure Causes French Biotech Stocks to Drop 43%

French Investor Leads €60M Financial Round for the Future of DNA Synthesis

New UK Joint Venture Bridges Gap between Top Universities and Big Pharmas

3 Facts Showing that the Future of Biotech Media is Online

Keytruda Combo! MSD Recruits German Biotech on Lymphoma PD-1 Trial

Gilead On Board, But Still No Easy Sailing for Galapagos with Phase IIa Failure

Virtual Reality: What is the future of Biotechnology Teaching and Training?

2011-2015: What a Fantastic 5 Years for European Biotech

This Potential First in Class Cancer Therapy Could Help Patients Avoid Eye Surgery

Also Using PD-L1 Cancer Treatments to Attack Alzheimer’s Disease

Nature’s Machines: Biohacking Evolution to Destroy Pollutants

What happened this week? Top 8 on Cancer, Inside J.P. Morgan and our new Event

Subscribe to our newsletter to get the latest biotech news!

The top biotech deals of March 2025

The biggest biotech funding rounds in March 2025

Join the webinar: AI in antibody discovery - from in silico analysis to AI-enabled data management

Beyond amyloid: The search for the next big thing in Alzheimer’s treatment

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

The top biotech deals of March 2025

The biggest biotech funding rounds in March 2025

Join the webinar: AI in antibody discovery - from in silico analysis to AI-enabled data management

Beyond amyloid: The search for the next big thing in Alzheimer’s treatment

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Subscribe to our newsletter

Get the latest biotech news directly to your inbox!

Newsletter Signup - Footer

Subscribe to our newsletter to get the latest biotech news!